Oxytocin in Multiparous Women

Launched by RAMBAM HEALTH CARE CAMPUS · Apr 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how continuous infusion of oxytocin, a hormone that helps with labor, affects the delivery time for women who have given birth before. The goal is to see if this method can help shorten the time it takes to deliver a baby without causing any issues for the mothers or their newborns. The study will compare continuous oxytocin infusion to a method where the hormone is given in intervals during labor.

To be eligible for this trial, women must be multiparous, meaning they have had one or more previous pregnancies, and they should be at least 37 weeks along in their current pregnancy with only one baby. They also need to be admitted to the hospital for labor induction, and the baby should be in the correct position for delivery. Women who are 18 years old or younger, those expecting more than one baby, or those with certain medical conditions that prevent vaginal delivery will not be able to participate. If you join this trial, you can expect to receive either the continuous or intermittent oxytocin infusion during your labor, and the team will monitor you and your baby closely throughout the process.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • multiparous women (women who have given birth one or more times in the past) with a singleton pregnancy that are admitted for induction of labor.
• • Women at gestational age of 370/7 or more.
• • Vertex presentation.
• Exclusion Criteria:
• • Age 18 and under.
• • High order gestation.
• • Women with contraindication for vaginal delivery.
• • Previous cesarean delivery.
• • Active labor.
• • Documented fetal anomalies.